成纤维细胞生长因子23对肾性贫血的研究进展  

The research progresses in fibroblast growth factor 23 on renal anemia

作　　者：张智艳 常沁涛[2] ZHANG Zhi-yan;CHANG Qintao(The First Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China;Department of Nephrology,The First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一临床医学院,太原030001 [2]山西医科大学第一医院肾内科,太原030001

出　　处：《中国血液净化》2023年第9期685-689,共5页Chinese Journal of Blood Purification

摘　　要：慢性肾脏病(chronic kidney disease,CKD)是全球公共卫生问题,发病率逐年攀升。该疾病特点是起病隐匿,不易察觉,随着肾脏逐渐衰竭,多种急慢性并发症随之而来,包括电解质紊乱、心力衰竭、贫血、矿物质代谢紊乱等。近年来有研究表明成纤维细胞生长因子23(fibroblast growth factor23,FGF23)不仅参与调节矿物质代谢,也与缺铁、炎症、红细胞生成素及低氧诱导因子有关,贫血是FGF23升高的强效驱动因素,FGF23升高与慢性肾脏病患者红细胞生成呈负相关。深入了解FGF23调控机制对治疗肾性贫血意义重大。Chronic kidney disease(CKD)is a global public health problem with an increasing incidence year by year.It is characterized by insidious onset and hard to be noticed at the beginning.With the gradual loss of kidney function,a variety of acute and chronic complications follow,including electrolyte disorders,heart failure,anemia,mineral metabolism disorders,and others.Recent studies have shown that fibroblast growth factor 23(FGF23)is involved not only in the regulation of mineral metabolism,but also in iron deficiency,inflammation,and the functions of erythropoietin and hypoxia-inducible factor.Anemia is a potent driver of FGF23,and FGF23 is negatively correlated with erythropoiesis in CKD patients.A comprehensive understanding of the regulatory mechanism of FGF23 is helpful for the treatment of renal anemia.

关 键 词：成纤维细胞生长因子23 肾性贫血 慢性肾脏病 

分 类 号：R692[医药卫生—泌尿科学]